CompletedPhase 3NCT04627025

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

Studying Chronic intestinal failure

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: VectivBio AG
Principal Investigator: Tomasz Masior
VectivBio AG
Intervention: apraglutide(drug)
Enrollment: 164 enrolled
Eligibility: 18 years · All sexes
Timeline: 2021 – 2024

Study locations (30)

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
Gastroenterology Group of Naples, Naples, Florida, United States
Northwestern University, Chicago, Illinois, United States
Henry Ford Medical Center - Columbus, Novi, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Mount Sinai Medical Center, New York, New York, United States
Duke University Hospital, Durham, North Carolina, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center, Center for Human Nutrition, Nashville, Tennessee, United States
University of Washington Medical Center, Seattle, Washington, United States
University Hospital Foundation Favaloro, Buenos Aires, Argentina
Universitair Ziekenhuis Leuven - Gasthuisberg, Leuven, Vlaams Brabant, Belgium
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04627025 on ClinicalTrials.gov

Other trials for Chronic intestinal failure

Additional recruiting or active studies for the same condition.

See all trials for Chronic intestinal failure →

← Back to all trials